[1] Park BJ,Wannemuehler KA,Marston BJ,et al.Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J].AIDS,2009,23(4):525-530.
[2] Husain S,Wagener MM,Singh N.Cryptococcus neoformans infection in organ transplant recipients:variables influencing clinical characteristics and outcome[J].Emerg Infect Dis,2001,7(3):375-381.
[3] Oladele RO,Denning DW.Burden of serious fungal infection in Nigeria[J].West Afr J Med,2014,33(2):107-114.
[4] Shahapur PR,Bidri RC.Recent trends in the spectrum of opportunistic infections in human immunodeficiency virus infected individuals on antiretroviral therapy in South India[J].J Nat Sci Biol Med,2014,5(2):392-396.
[5] Boulware DR,Rolfes MA,Rajasingham R,et al.Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast[J].Emerg Infect Dis,2014,20(1):45-53.
[6] Lee SC,Casadevall A,Dickson DW.Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis[J].Am J Pathol,1996,148(4):1267-1274.
[7] Lee SC,Dickson DW,Casadevall A.Pathology of cryptococcal meningoencephalitis:analysis of 27 patients with pathogenetic implications[J].Hum Pathol,1996,27(8):839-847.
[8] Binnicker MJ,Jespersen DJ,Bestrom JE,Rollins LO.Comparison of four assays for the detection of cryptococcal antigen[J].Clin Vaccine Immunol,2012,19(12):1988-1990.
[9] Lindsley MD,Mekha N,Baggett HC,et al.Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis[J].Clin Infect Dis,2011,53(4):321-325.
[10] Jarvis JN,Percival A,Bauman S,et al.Evaluation of a novel point-of-care cryptococcal antigen test on serum,plasma,and urine from patients with HIV-associated cryptococcal meningitis[J].Clin Infect Dis,2011,53(10):1019-1023.
[11] Gates-Hollingsworth MA,Kozel TR.Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen[J].Clin Vaccine Immunol,2013,20(4):634-635.
[12] Hansen J,Slechta ES,Gates-Hollingsworth MA,et al.Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid[J].Clin Vaccine Immunol,2013,20(1):52-55.
[13] IMMY Cryptococcal Antigen Lateral Flow Assay[EB/OL].[2012-7-29].http://www.immy.com/products/cryptococcal-antigen-lateral-flow-assay-lfa/.
[14] Kwizera R,Nguna J,Kiragga A,et al.Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100[J].PLoS One,2014,9(7):e103156.
[15] 王劲,张雪林,张三泉,等.隐球菌性脑膜脑炎的CT、MRI影像表现及其诊断意义[J].中国医学影像学杂志,2003,11(3):194-196.
[16] Bicanic T,Wood R,Meintjes G,et al.High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients:a randomized trial[J].Clin Infect Dis,2008,47(1):123-130.
[17] Hamill RJ,Sobel JD,El-Sadr W,et al.Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis:a randomized,double-blind clinical trial of efficacy and safety[J].Clin Infect Dis,2010,51(2):225-232.
[18] Brouwer AE,Rajanuwong A,Chierakul W,et al.Combination antifungal therapies for HIV-associated cryptococcal meningitis:a randomised trial[J].Lancet,2004,363(9423):1764-1767.
[19] Pappas PG,Chetchotisakd P,Larsen RA,et al.A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis[J].Clin Infect Dis,2009,48(12):1775-1783.
[20] Loyse A,Wilson D,Meintjes G,et al.Comparison of the early fungicidal activity of high-dose fluconazole,voriconazole,and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis[J].Clin Infect Dis,2012,54(1):121-128.
[21] Day JN,Chau TT,Lalloo DG.Combination antifungal therapy for cryptococcal meningitis[J].N Engl J Med,2013,368(26):2522-2523.
[22] Bozzette SA,Larsen RA,Chiu J,et al.A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome.California Collaborative Treatment Group[J].N Engl J Med,1991,324(9):580-584.
[23] Kirk O,Reiss P,Uberti-Foppa C,et al.Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy[J].Ann Intern Med,2002,137(4):239-250.
[24] Vibhagool A,Sungkanuparph S,Mootsikapun P,et al.Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy:a prospective,multicenter,randomized study[J].Clin Infect Dis,2003,36(10):1329-1331.
[25] Makadzange AT,McHugh G.New approaches to the diagnosis and treatment of cryptococcal meningitis[J].Semin Neurol,2014,34(1):47-60.
[26] Zolopa A,Andersen J,Powderly W,et al.Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections:a multicenter randomized strategy trial[J].PLoS One,2009,4(5):e5575.
[27] Abdool KSS,Naidoo K,Grobler A,et al.Timing of initiation of antiretroviral drugs during tuberculosis therapy[J].N Engl J Med,2010,362(8):697-706.
[28] Makadzange AT,Ndhlovu CE,Takarinda K,et al.Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa[J].Clin Infect Dis,2010,50(11):1532-1538.
[29] Boulware DB,Meya DB,Muzoora C,et al.ART Initiation within the First 2 Weeks of Cryptococcal Meningitis Is Associated with Higher Mortality:A Multisite Randomized Trial.In:20th Conference on Retroviruses and Opportunistic Infections.2013,March 3-6,2013;Atlanta,GA.Oral abstract 144.
[30] Bisson GP,Molefi M,Bellamy S,et al.Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis[J].Clin Infect Dis,2013,56(8):1165-1173.
[31] Jarvis JN,Lawn SD,Vogt Met al.Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa[J].Clin Infect Dis,2009,48(7):856-862.
[32] Jarvis JN,Harrison TS,Lawn SDet al.Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa[J].PLoS One,2013,8(7):e69288.
[33] Hole CR,Wormley FL Jr.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis:lessons learned from animal models[J].Front Microbiol,2012,3:291.
[34] Netea MG,Brouwer AE,Hoogendoorn EH,et al.Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia:defective cytokine production and reversal by recombinant interferon- gamma therapy[J].Clin Infect Dis,2004,39(9):e83-87.
[35] Jarvis JN,Meintjes G,Rebe K,et al.Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis:a randomized controlled trial[J].AIDS,2012,26(9):1105-1113.
[36] Pappas PG.Editorial Commentary:An expanded role for therapeutic lumbar punctures in newly diagnosed AIDS-associated cryptococcal meningitis[J].Clin Infect Dis,2014,59(11):1615-1617.
[37] Rolfes MA,Hullsiek KH,Rhein J,et al.The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis[J].Clin Infect Dis,2014,59(11):1607-1614.
[38] Wang H,Ling C,Chen C,et al.Evaluation of ventriculoperitoneal shunt in the treatment of intracranial hypertension in the patients with cryptococcal meningitis:a report of 12 cases[J].Clin Neurol Neurosurg,2014,124:156-160.
[39] 黄欣,温海,姚志荣,等.颅内接种热灭活隐球菌对小鼠隐球菌脑膜脑炎作用的研究[J].中华皮肤科杂志,2003,36(8):457-460.
[40] Barluzzi R,Brozzetti A,Mariucci G,et al.Establishment of protective immunity against cerebral cryptococcosis by means of an avirulent,non melanogenic Cryptococcus neoformans strain[J].J Neuroimmunol,2000,109(2):75-86.
[41] Devi SJ,Schneerson R,Egan W,et al.Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines:synthesis,characterization,and immunogenicity[J].Infect Immun,1991,59(10):3700-3707. |
